CH Predicts Adverse Cardiac Remodeling
Clonal hematopoiesis (CH) driver mutations increase myocardial inflammation via macrophage inflammasome, interleukin-1, and interleukin-6 expression. Patients with dilated cardiomyopathy (DCM) and CH have a lower chance of reverse cardiac remodeling, independent of germline mutation in DCM-associated genes. Immunomodulatory therapy may ultimately improve cardiac remodeling in DCM.